Zantac (ranitidine), a popular heartburn medication, has been linked to several types of cancer. Zantac was used to treat and prevent stomach and intestinal ulcers, as well as conditions in which the stomach produces too much acid, such as gastroesophageal reflux disease (GERD), treatment of Zollinger-Ellison syndrome and other conditions which cause heartburn or sour stomach. Millions of Americans have used Zantac to relieve heartburn and stomach ulcers.
The U.S. Food and Drug Administration (FDA) released a statement in September 2019 warning that over-the-counter varieties of Zantac contained an impurity called Nnitrosodimethylamine (NDMA) at low levels, which is classified as a probable human carcinogen linked to several types of cancer.
In April of 2020, the FDA recommended the removal of both prescription and over-the-counter versions of ranitidine, which is the active ingredient in the heartburn and acid reflux medicine Zantac. Testing by the FDA has confirmed that NDMA was present in ranitidine, and that even when stored under normal conditions, levels of NDMA increase substantially when stored at higher temperatures. This means that the longer this medication sat on a store shelf or in a medicine cabinet, the greater the level of NDMA. Although ingestion of low levels of NDMA is not linked to an increased risk of cancer, the FDA has stated that “sustained higher levels of exposure may increase the risk of cancer in humans.” This means that individuals who used Zantac for prolonged periods of time are at an increased risk of cancer.
PWHD is currently investigation claims for individuals who have used Zantac (ranitidine) and who have been diagnosed with certain types of cancer, including: bladder, liver, stomach, colon, kidney and pancreatic cancer.
If you or a loved one regularly used Zantac or any other product containing ranitidine and have been diagnosed with cancer, our products liability attorneys would like to talk to you. You can discuss your potential claim with us at no cost by calling us today at 757-223-4545 or filling out our online contact form.